risedronic acid has been researched along with Metabolic Syndrome in 1 studies
Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.
Metabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Adverse event incidence was marginally higher in DL compared with non-DL (Relative risk 1." | 2.82 | Efficacy and Safety of Risedronate in Osteoporosis Subjects with Comorbid Diabetes, Hypertension, and/or Dyslipidemia: A Post Hoc Analysis of Phase III Trials Conducted in Japan. ( Inoue, D; Muraoka, R; Nishizawa, Y; Okazaki, R; Sugimoto, T, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Inoue, D | 1 |
| Muraoka, R | 1 |
| Okazaki, R | 1 |
| Nishizawa, Y | 1 |
| Sugimoto, T | 1 |
1 trial available for risedronic acid and Metabolic Syndrome
| Article | Year |
|---|---|
Efficacy and Safety of Risedronate in Osteoporosis Subjects with Comorbid Diabetes, Hypertension, and/or Dyslipidemia: A Post Hoc Analysis of Phase III Trials Conducted in Japan.
Topics: Adult; Aged; Bone Density; Bone Density Conservation Agents; Comorbidity; Diabetes Mellitus; Double- | 2016 |